NCT04034238 2023-08-01Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid TumorsNational Institutes of Health Clinical Center (CC)Phase 1 Completed19 enrolled 22 charts